5-氨基-2-氟苯甲酸 | 56741-33-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-2-氟苯甲酸
• 中文别名: 3-氨基-6-氟苯甲酸；5-氨基-2氟苯甲酸；2-氟-5-氨基苯甲酸
• 英文名称: 5-amino-2-fluorobenzoic acid
• 英文别名: 2-fluoro-5-aminobenzoic acid
• CAS: 56741-33-4
• 化学式: C₇H₆FNO₂
• mdl: MFCD00077449
• 分子量: 155.129
• InChiKey: WYGAIOJWQDRBRJ-UHFFFAOYSA-N

物化性质

• 熔点：
  190 °C
• 沸点：
  351.3±27.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥的地方。同时，确保工作环境有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Amino-2-fluorobenzoic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-Amino-2-fluorobenzoic acid
Ingredient name:
CAS number: 56741-33-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6FNO2
Molecular weight: 155.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-2-氟苯甲酸 在 bis(1,5-cyclooctadiene)nickel (0) 、 potassium tert-butylate 、 碘 、 三乙胺 、 三甲氧基磷 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 、 N,N-dimethyl-d₆-formamide 为溶剂， 反应 6.0h， 生成 tert-butyl (2-(4-methoxyphenyl)-1-oxo-3,4-diphenyl-1,2-dihydroisoquinolin-7-yl)carbamate
  参考文献：
  名称：

  镍催化的芳酰胺与炔烃的 CF/NH 环化：在温和反应条件下激活 CF 键

  摘要：

  邻氟取代的芳香酰胺与炔烃的 Ni 催化反应导致 CF/NH 环化，得到 1(2H)-异喹啉酮。反应成功的关键是使用 KOBut 或什至弱碱，例如 Cs2CO3。该反应在没有配体的情况下在温和的反应条件 (40-60 °C) 下进行。竞争实验和 DFT 计算表明，这种 Ni 催化的 CF/NH 环化的途径涉及 NH 去质子化、CF 键的氧化加成、炔烃的迁移插入和还原消除途径以形成 1(2H)-异喹啉酮衍生物。

  DOI：

  10.1021/jacs.0c08512
• 作为产物：
  描述：

  邻氟苯甲酸 在 palladium on activated charcoal 硫酸 、 硝酸 、 环己烯 作用下， 以 乙醇 为溶剂， 反应 6.75h， 生成 5-氨基-2-氟苯甲酸
  参考文献：
  名称：

  7-苯并恶唑-2-基和7-苯并噻唑-2-基-6-氟喹诺酮类化合物的合成

  摘要：

  氟喹诺酮类，7-苯并恶唑-2-基-1-乙基-6-氟-1,4-二氢-4-氧喹啉-3-羧酸和7-苯并噻唑-2-基-1-乙基-6-氟-合成了1，4-二氢-4-氧代喹啉-3-羧酸。这些化合物是通过使用Gould-Jacobs途径制得的喹啉环系统获得的。通过5-氨基-2-氟苯甲酸与2-氨基苯酚或2-氨基硫代苯酚的环化脱水反应，可得到所需的苯胺，3-苯并恶唑-2-基-4-氟苯胺和3-苯并噻唑-2-基-4-氟苯胺。分别使用多磷酸。

  DOI：

  10.1002/jhet.5570350610

文献信息

• Benzene Sulfonamide Thiazole and Oxazole Compounds
  申请人：Adams Jerry Leroy

  公开号：US20090298815A1

  公开（公告）日：2009-12-03

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺胺和噁唑磺胺化合物，含有这些化合物的组合物，以及用作药物制剂的制备方法和使用方法。
• [EN] NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE 3,3-DIMÉTHYLTÉTRAHYDROQUINOLÉINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011128251A1

  公开（公告）日：2011-10-20

  A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R5 have the significance given in claim 1, can be used as a medicament.

  化合物的化学式（I）及其药用盐，其中R1至R5具有权利要求1中给定的含义，可用作药物。
• NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES
  申请人：Chen Li

  公开号：US20110257151A1

  公开（公告）日：2011-10-20

  A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R 1 to R 5 have the significance given in claim 1 , can be used as a medicament.

  式（I）的化合物以及其药学上可接受的盐，其中R1至R5具有权利要求1中给定的含义，可用作药物。
• [EN] PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES<br/>[FR] COMPOSES PYRROLIQUES DESTINES AU TRAITEMENT DE MALADIES INDUITES PAR PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003101959A1

  公开（公告）日：2003-12-11

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

  式(I)的化合物或其药学上可接受的衍生物：其中A、R1、R2a、R2b、Rx、R8和R9如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学中的用途，特别是它们在治疗前列腺素介导的疾病，如疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病中的用途。
• New thiadiazoles and their use as phosphodiesterase-7 inhibitors
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1193261A1

  公开（公告）日：2002-04-03

  The invention provides 1,3,4-thiadiazoles having the following formula (I): in which, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted, R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted, R3 is X2-R'3, in which X2 is a binding group and R'3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, the process for their preparation and their use for the manufacture of a medicament for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.

  该发明提供具有以下式（I）的1,3,4-噻二唑： 其中， R1是烷基，烯基，炔基，环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基团，可选择性取代， R2是烷基，烯基，炔基，环烷基，杂环烷基，环烯基或芳基，可选择性取代， R3是X2-R'3，其中X2是一个结合基团，R'3是环烷基，杂环烷基，环烯基，芳基，杂芳基或多环基团；可选择性取代，或它们的药学上可接受的衍生物， 它们的制备方法及其用于制备治疗PDE7抑制剂相关疾病的药物的用途。